In Vitro Studies on the Effect of Dialysis Solutions on Peritoneal Leukocytes

Within the limitations of the various experimental protocols there appears to be agreement in the literature that unused dialysis fluids, at least when studied in vitro, adversely affect multiple leukocyte functions. The effects of dialysis fluids on leukocytes that have been reported to date include: 1. Decreased cell viability of PMNs, PM phis, PBMCs, and lymphocytes; 2. Inhibited phagocytosis and bacterial killing of various microorganisms by PM phis, PMNs, and peripheral blood leukocytes; 3. Reduced secretion of leukotrienes (LTB4, LTC4) from peritoneal and peripheral blood PMNs and PBMCs; 4. Reduced secretion of prostaglandins (PGE2, TXB2 and 6-keto-PGF1 alpha) from PM phi; 5. Decreased production of many cytokines including TNF alpha, IL-8, and IL-6 in PM phis and PBMCs. In addition, several studies targeting the potential mechanisms by which dialysis solutions inhibit leukocyte function identified the initial low pH of the fluids in combination with their lactate content as being of primary relevance, since they may lead to a rapid intracellular acidification of leukocytes. Moreover, some studies indicated the importance of fluid hyperosmolarity and excessive glucose concentrations. These results are indirectly supported by recent in vitro investigations of alternative fluids, which showed improved leukocyte function following exposure to solutions with neutral pH, bicarbonate buffer instead of lactate, or normal osmolarity due to use of an alternative osmotic agent (e.g., glucose polymer). In conclusion, the evidence obtained during in vitro experimentation suggests that current dialysis fluids are, indeed, not biocompatible. However, whether this also bears physiological relevance in vivo remains to be established in controlled clinical trials comparing conventional fluids to alternative solutions with improved biocompatibility. With regard to the future development of in vitro models for biocompatibility assessment, the following guidelines are suggested: 1. Cell functional parameters should be studied in more than one cell population; 2. Depending on which fluid aspect is under investigation, short or even very short exposure times should be used (e.g., < 30 min for pH/buffer studies; < 4 hours for osmolality/osmotic agent studies); 3. In case the parameter/readout of interest requires longer study periods than indicated above (e.g., studies of cytokine induction or surface receptor expression), preincubation/recovery models should be preferred over coincubation experiments.

[1]  N. Topley,et al.  In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  T. Liberek,et al.  Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. , 1993, Nephron.

[3]  A. Douvdevani,et al.  The Effect of Peritoneal Dialysis Fluid on the Release of Il-113 and Tnfa by Macrophages/Monocytes , 1993 .

[4]  A. Donker,et al.  Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  T. Liberek,et al.  Cell Function and Viability in Glucose Polymer Peritoneal Dialysis Fluids , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[6]  T. Liberek,et al.  Peritoneal dialysis fluid inhibition of phagocyte function: effects of osmolality and glucose concentration. , 1993, Journal of the American Society of Nephrology : JASN.

[7]  A. Donker,et al.  In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. , 1993, Clinical nephrology.

[8]  T. Liberek,et al.  Impact of Peritoneal Dialysis Solutions on Peritoneal Immune Defense , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[9]  H. Schambye,et al.  The Cytotoxicity of Continuous Ambulatory Peritoneal Dialysis Solutions with Different Bicarbonate/Lactate Ratios , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[10]  M. Davies,et al.  Cytokine Networks in Continuous Ambulatory Peritoneal Dialysis: Interactions of Resident Cells during Inflammation in the Peritoneal Cavity , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[11]  A. Douvdevani,et al.  The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[12]  J. Chemnitz,et al.  Bicarbonate versus Lactate-Based Capd Fluids: A Biocompatibility Study in Rabbits , 1992, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[13]  P. Schollmeyer,et al.  Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. , 1992, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[14]  E. Köttgen,et al.  Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. , 1992, American journal of nephrology.

[15]  E. Köttgen,et al.  Leukotriene B4 and tumor necrosis factor release from leukocytes: effect of peritoneal dialysate. , 1991, Nephron.

[16]  A. Donker,et al.  Another reason to restrict the use of a hypertonic, glucose-based peritoneal dialysis fluid: its impact on peritoneal macrophage function in vivo. , 1991, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[17]  N. Topley,et al.  Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  Z. Nawab,et al.  Superoxide Generation by Neutrophils after Exposure to a Conventional Peritoneal Dialysis Solution for Different Time Periods , 1990, The International journal of artificial organs.

[19]  D. Lloyd,et al.  The effect of dialysate on peritoneal phagocyte oxidative metabolism. , 1988, Kidney international.

[20]  J. Daugirdas,et al.  Suppression of Neutrophil Superoxide Production by Conventional Peritoneal Dialysis Solution , 1988, The International journal of artificial organs.

[21]  D. Lloyd,et al.  Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. , 1986, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  B. Gallimore,et al.  Cytotoxicity of commercial peritoneal dialysis solutions towards peritoneal cells of chronically uremic mice. , 1986, Nephron.

[23]  E. Neilson,et al.  Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients. , 1984, Kidney international.

[24]  A. Duwe,et al.  Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro , 1981, Infection and immunity.

[25]  R. Pyper Peritoneal Dialysis , 1948, The Ulster medical journal.